Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 2511204 approvals

BIO-FD&C CO.,LTD.

Official website

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

As of 2026-10-10, BIO-FD&C CO.,LTD. has 4 Korean MFDS device approvals, 16 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2005 and listed on KOSDAQ in 2022, BIO-FD&C develops and manufactures plant-cell-derived bioactive and pharmacological materials using its plant cell design and culture platform. Using SMART-RC2 mass-culture technology, it produces transgenic plant cell lines including recombinant growth factors, phytopeptides, and rose cell lines, and holds a pipeline of stem-cell stimulant P334-CT (Poripha334), incontinence treatment KSF-D (Kurarinone), and gastric cancer/gastritis treatment HelicoMab. It runs the Plant Cell Institute in Incheon (21 researchers) and the Pharmaceutical Nano Materials Institute in Gwangju-Jeonnam (13 researchers), holds about 250 plant cell lines with 120 cryopreserved, and supplies 25 mass-cultured cell lines to Givaudan, GINZATOMATO, SIYANLI, and BENEV.

Products & technology

  • Plant cell lineMaterial for cosmeceuticals, health functional foods, and pharmaceuticals
  • Recombinant growth factorCosmeceutical material
  • PhytopeptideCosmeceutical material
  • Rose cell lineTransgenic plant cell line material
  • PDRN (Polydeoxyribonucleotide)Cosmetic material extraction technology

Regulatory approvals

data.go.kr

4 Korean MFDS device approvals · 2024–2026

  • MFDSDressing, fluid-impermeable film2026-08-27
    Product approval · Class 2제인 26-4795 호
  • MFDSDressing, fluid-impermeable film2026-04-06
    Product approval · Class 2제인 26-4303 호
  • MFDSDressing, fluid-impermeable film2025-12-04
    Product approval · Class 2제인 25-5132 호
  • MFDSDressing, fluid-impermeable film2024-10-17
    Product approval · Class 2제인 24-947 호

R&D and key agreements

Source: DART corporate disclosure

P334-CT(포피라334) · 줄기세포촉진 · 시약 · Plant-cell-derived pharmacological material pipeline

KSF-D(쿠라리논) · 요실금치료 · 신약 · Plant-cell-derived pharmacological material pipeline

HelicoMab · 위암/위염치료 · 신약 · Plant-cell-derived pharmacological material pipeline

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 6 more publications

Patents

KIPRIS · applicant-matched
Show 202 more patents

AI reads

MAA server logs · IP-verified
203
Times AI engines pulled BIO-FD&C CO.,LTD.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

202
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

8
live 0
Last 7 days
160
live 1
Last 30 days
203
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot154
  • GoogleGoogleOther37
  • PerplexityPerplexityBot8
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 26, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for BIO-FD&C CO.,LTD. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

HANS BIOMED CORPORATION1 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

DONGWHA PHARM.CO.,LTD1 shared

Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.

WonIk Co.,LTD1 shared

WonIk, founded in 1983 and KOSDAQ-listed in 1997, operates pressure sensor, dermo-cosmetic, and medical device distribution businesses.

Tego Science, Inc.1 shared

Tego Science makes cell therapies Holoderm and Rosmir, and sells the 3D skin model Neoderm for CDMO and animal-alternative testing.

DaehanPharmaceutical1 shared

Daehan Pharmaceutical, founded in 1963 and KOSDAQ-listed in 1994, manufactures intravenous fluid pharmaceuticals.

PharmaResearch Co., Ltd.1 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

Humedix Co., Ltd.1 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

Wonbiogen Co.,Ltd.1 shared

Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.

Dong-A Socio Holdings Co.,Ltd1 shared

Founded 1949, KOSPI-listed 1970, Dong-A Socio Holdings makes Bacchus and pharma/non-pharma goods, allied with Meiji Seika on biosimilars.

KOLMAR KOREA CO.,LTD1 shared

Founded and listed on KOSPI in 2012 upon spin-off from the former Kolmar Korea, KOLMAR KOREA runs cosmetics ODM, prescription drugs, and packaging.

Keeps Biopharma Inc.1 shared

Founded in 2000 and listed on KOSDAQ in 2017, Keeps Biopharma transitioned from OLED equipment to pharmaceuticals through its 2025 merger with Korea Global Pharm.

DongKookPharmaceuticalCo.,Ltd.1 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition